Why your weight loss stalls on a GLP-1 - and what a plateau really means

TL;DR

• A plateau usually isn't the drug quitting - a smaller body burns fewer calories, resting metabolic rate falls, and intake and expenditure settle at a new equilibrium.
• A plateau and primary non-response are different problems - one is a response that levelled off, the other never started.
• Primary non-response has a real differential - inter-individual variability, adherence and administration, unverified compounded or grey-market product, untreated sleep apnoea, weight-promoting medications, and endocrine causes.
• Scale weight is a crude instrument - someone losing fat while holding muscle can look flat while body composition and cardiometabolic markers improve.
• Dose–response in this class is a curve, not a straight line - past the flat part, more input buys side effects rather than more result.
• A maintained loss is a clinical win - and where more is genuinely needed, the lever is usually a second mechanism chosen with a physician, not a bigger solo dose.

MAB-reviewed and cleared for the Malaysian market (Jun 2026). Educational content, not medical advice. Compound and trial data lead. No doses, schedules or self-directed dose changes appear here - adjusting, switching or stacking is a physician decision.

Updated August 2026: separates primary non-response - never having responded meaningfully in the first place - from a plateau, which is a response that levelled off. The article previously treated them as one problem; they have different explanations and only one of them is equilibrium.

---

A weight-loss plateau on a GLP-1 feels like failure or like the medication "stopped working." It's usually neither. As you lose weight, your body needs fewer calories to run a smaller frame, your resting metabolic rate falls, and appetite signalling recalibrates around the drug - until intake and a now-lower expenditure meet and the scale settles. That's physiology working as designed, not the drug quitting. The honest takeaway up front: a maintained loss is a clinical win, and the right response to a plateau is to check the fundamentals with a physician - not to panic-escalate the dose.

Here's what's actually happening, and what genuinely helps.

First: is this a plateau, or did it never start?

These are two different problems and they get talked about as one. Before anything else, work out which one you're actually in - because the explanations barely overlap.

The rest of this article is mostly about plateaus. The next section is about the other one.

Primary non-response: when it never worked from the start

Primary non-response means there was never a meaningful response - not that a response faded. It's a recognised phenomenon in this drug class, it isn't rare, and it deserves a straighter explanation than the internet gives it. Here's the honest list of what can sit behind it.

Genuine inter-individual variability. People respond differently to these medications, and that variation is real, documented across the trials, and not a character flaw. Trial averages are averages: some participants land well above the headline number and some land well below it. Being at the low end of a response distribution is a biological outcome, not a discipline problem, and the framing matters because the shame version of this story keeps people from going back to their prescriber.

Adherence and administration. Unglamorous, and one of the commonest explanations. Missed doses, gaps in supply, incorrect storage, or a technique problem that means the full amount never actually went in. None of that is a comment on someone's seriousness - it's the sort of thing that gets found by a prescriber walking through the practicalities, and it's worth checking before anything more exotic.

Is the product what it says it is? This one matters most where the material is compounded or bought from a grey-market source. If the concentration is not what the label claims, or the contents are not what the label claims, then "non-response" isn't a fact about the person at all - it's a fact about the vial. There is no way to reason your way past this from the outside, because you cannot verify the contents of something you can't test. (See is compounded GLP-1 legal? for the regulatory picture.) With regulated, prescribed product this explanation is off the table, which is one of the underrated arguments for staying inside the system.

Unrecognised contributors nobody looked for. Several common conditions push hard in the opposite direction and are routinely missed:

• Untreated sleep apnoea - extremely common in this population, frequently undiagnosed, and it drags on metabolic health, appetite regulation and recovery.
• Medications that promote weight gain - several widely-prescribed classes do this, including some psychiatric, neurological, steroid and diabetes medications. People are often on them for good reasons and nobody joined the dots.
• Endocrine causes - thyroid disease and other hormonal conditions belong on the list of things a clinician rules in or out rather than assumes away.

None of these are self-diagnosable and none of them are fixed by anything you do with the medication.

"Response" measured only by the bathroom scale is a bad instrument. This is the most under-appreciated point in the whole discussion. Scale weight is a single crude number that bundles fat, lean mass, fluid and gut contents together. Someone who has lost fat while holding or building muscle can show a nearly flat scale and a genuinely improved body - and the cardiometabolic changes these drugs produce (blood pressure, lipids, glycaemic markers, inflammatory markers, liver fat) don't announce themselves on a scale at all. Some people labelled "non-responders" by weight are responding on measures that were never checked. Body composition and bloodwork are how you find out. (Related: losing fat, not muscle, on a GLP-1.)

Where all of this goes: back to the prescriber. Every single item above resolves to a clinical review - history, medication list, bloodwork, a look at what's actually being measured, and a conversation about whether something was missed. Nothing on that list is something to act on yourself, and none of it is a reason to change what you're taking on your own initiative. The point of naming these causes isn't to hand anyone a fix; it's so you can walk into the appointment knowing that "it just didn't work for me" is not the end of the enquiry.

Plateau: what people think vs. what's happening

Why the stall happens

Three forces converge, and they're the same ones behind weight regain:

• A smaller body burns fewer calories. The deficit that drove early loss shrinks as you do.
• Resting metabolic rate drops - often more than size alone predicts (metabolic adaptation).
• Appetite recalibrates around the medication, so the same dose exerts relatively less suppression than it did at the start.

When intake and expenditure rebalance, weight settles. The drug is still doing its job; the system has simply found a new set point.

There's also a pharmacological point worth understanding here, and it applies to both scenarios: dose–response in this class is a curve, not a straight line. It rises and then flattens, and past the flat part more input stops buying more output while continuing to buy side effects. That's why "just go higher" isn't the reflex answer to either a plateau or a poor initial response - see what dose–response actually looks like. And it's why the "drug holiday to resensitize" idea doesn't hold up either: the resensitizing myth.

What a physician actually weighs

This is where supervision earns its place - the response to a plateau is a sequence of checks, not a reflex:

• Confirm adherence and titration. Is the dose actually at a therapeutic level, taken consistently? A surprising share of "plateaus" are really under-dosing or missed doses.
• Revisit protein and resistance training. More muscle means a higher metabolic floor - sometimes the lever that breaks a stall isn't the drug at all.
• Ask whether this is a plateau or the destination. A durable, healthy weight that's holding may be the goal, not a problem to solve.
• Check what's being measured. Body composition and bloodwork can show progress a stalled scale is hiding.
• Only then, consider the dose or the mechanism. Whether to escalate, switch or add is a clinical decision made on the individual's data.

The add-on frontier, honestly

If a true plateau needs more, the interesting science is adding a second mechanism rather than just more of the first. Amylin analogues like cagrilintide work through a separate satiety pathway, and the combination with semaglutide (CagriSema) reached about −20.4% in a phase 3 trial (REDEFINE 1, NEJM 2025) - more than either component alone. That's the real rationale behind "stacking a second pathway." But - and this matters - "switch or stack" is a supervised decision, never a self-directed cycle, and there are diminishing returns to simply climbing the dose of a single agent. The goal is the right mechanism for the person, not the biggest number on the syringe.

The bottom line - and where to start

A plateau is equilibrium, not defeat. Before assuming the drug failed, the honest move is to check adherence, dose, protein and training - and to ask whether the weight you've reached is actually the goal. Never having responded at all is a different question with a different differential: variability, adherence, whether the product is what it claims to be, missed contributors like sleep apnoea or weight-promoting medications or endocrine causes, and the possibility that the scale is the wrong instrument. Both roads end at the same door - a prescriber with your full picture in front of them. If more is genuinely needed, the smart lever is often a second mechanism, chosen with a physician, not a bigger solo dose. Reframed that way, the stall stops being a crisis and becomes a decision point.

Explore it with verified supply. Every Vivre Labs lot is independently tested and the certificate of analysis is published, so you know exactly what is in the vial. Explore cagrilintide.

Frequently asked questions

What's the difference between a plateau and primary non-response? A plateau means you responded and then levelled off - usually a new energy-balance equilibrium. Primary non-response means there was never a meaningful response to begin with. Different causes, different conversations with your prescriber.

Does primary non-response mean the drug will never work for me? Not necessarily, and it's the wrong question to answer yourself. It's a prompt for a clinical review - adherence and administration, whether the product is verified, unrecognised contributors like sleep apnoea or weight-promoting medications or endocrine conditions, and whether "response" is being judged on scale weight alone when body composition and cardiometabolic markers weren't checked.

Can the medication itself be the problem? Where material is compounded or comes from a grey-market source, yes - if the contents or concentration aren't what the label says, apparent non-response may be a fact about the product rather than the person. That's not something you can verify yourself.

Related reading

• What dose–response actually looks like - why the curve flattens, and what that means for "just go higher"
• GLP-1 plateau & "resensitizing": myth vs reality - is a drug holiday a real fix?
• Is compounded GLP-1 legal? - why "what's actually in it" is a live question
• Keeping the weight off after you stop - the rebound problem behind the same physiology
• Losing fat, not muscle, on a GLP-1 - muscle as the metabolic floor that resists stalls
• Mounjaro vs Wegovy vs Ozempic: the honest comparison - when switching molecule is the right lever
• Cagrilintide as a GLP-1 bridge or stack - adding a second mechanism

---

Educational content, not medical advice. Decisions to maintain, adjust, switch or combine any medication must be made with a supervising physician. Nothing here is a basis for changing, escalating or stopping a medication on your own. Trial figures describe study populations; individual results vary. Claims for the Malaysian market were reviewed and cleared by MAB (Jun 2026).

Primary references

• Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab. 2022 (PMID 35441470). (metabolic adaptation context)
• CagriSema (cagrilintide–semaglutide), REDEFINE 1. N Engl J Med. 2025. (−20.4%; second-pathway rationale)
• Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387:205–216.
• Inter-individual variability in weight response is visible in the distribution of outcomes reported across the STEP and SURMOUNT programmes; the primary non-response section is written qualitatively and states no thresholds or response-rate figures.